MI-CP151 was a stage 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre examine to evaluate a number of intravenous doses of sifalimumab, in adult sufferers with dermatomyositis or polymyositis (NCT00533091). Principal demo aims ended up To guage the safety and tolerability of sifalimumab in dermatomyositis or polymyositis patients, although one of https://henrya332pak5.wikiconversation.com/user